Clinical ESCORT‐1st and JUPITER‐6 trials conducted by our group showed that PD‐1 mAb combined with paclitaxel and cisplatin (TP) significantly improved PFS and OS in patients with advanced ESCC.3, 4. Here, PDCD1 is linked to esophageal squamous cell carcinoma.